From £6.99 per month
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares


Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Results: YGEN

Search articles by EPIC code

Buy Yourgene - target 0.6p

On 21st December, with its shares having previously closed at 1.85p, Yourgene Health* (YGEN) announced a “capital raising” for “not less than £5.0 million” stated to “provide near-term working capital; and facilitate further restructuring of the group's cost base, removing £2.0 million of annual operating expenditure. The company will also utilise any additional net proceeds to fund regulatory approvals and existing product enhancements”. I.e. it was cash crunch ahoy and, having left the fundraise to that point and with stock market conditions dreadful, the raising was at… 0.30p per share! Unsurprisingly, that sunk the shares, but with new capital now raised and sentiment arguably having hit rock bottom, we see some good recovery potential from a current 0.38p offer price. (now 0.41p)

Yourgene dismal trading update: the Lady doth protest…surely a placing needed

Once upon a time, Yourgene (YGEN) was a growth stock, the sort of company where shoot the lights out sales increases justified a lofty multiple which might allow for yet another fund raise. How times have changed. Today’s trading update was piss poor and, whatever bearded boss Lynn Rees might say,  there must be a very high chance of a 2023 placing, as I warned three weeks ago HERE.


Yourgene Health – trading update & company chat. Share price fall justified?

A trading update from Yourgene Health (YGEN) commences that “the stronger trading patterns being observed in H2 compared to the first 6 months of the financial year mean that double-digit revenue growth is expected for the full year” (to 31st March 2021). However, the shares are currently around 9% lower in response, at circa 12p, with the update also including “the ongoing impact of COVID-19 on ordering patterns in UK and international commerce is expected to result in full year revenue being below consensus market estimates”. Having spoken to the company, here’s the detail...

Page 1 of 5 (48 articles)
Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Complete Coverage

Recent Comments